Skip to main content
PLOS One logoLink to PLOS One
. 2021 May 27;16(5):e0252318. doi: 10.1371/journal.pone.0252318

Latent transition analysis of cardiac arrest patients treated in the intensive care unit

Lifeng Xing 1, Min Yao 2, Hemant Goyal 3, Yucai Hong 1,*, Zhongheng Zhang 1,4,*
Editor: Saraschandra Vallabhajosyula5
PMCID: PMC8158944  PMID: 34043699

Abstract

Background and objective

Post-cardiac arrest (CA) syndrome is heterogenous in their clinical presentations and outcomes. This study aimed to explore the transition and stability of subphenotypes (profiles) of CA treated in the intensive care unit (ICU).

Patients and methods

Clinical features of CA patients on day 1 and 3 after ICU admission were modeled by latent transition analysis (LTA) to explore the transition between subphenotypes over time. The association between different transition patterns and mortality outcome was explored using multivariable logistic regression.

Results

We identified 848 eligible patients from the database. The LPA identified three distinct subphenotypes: Profile 1 accounted for the largest proportion (73%) and was considered as the baseline subphenotype. Profile 2 (13%) was characterized by brain injury and profile 3 (14%) was characterized by multiple organ dysfunctions. The same three subphenotypes were identified on day 3. The LTA showed consistent subphenotypes. A majority of patients in profile 2 (72%) and 3 (82%) on day 1 switched to profile 1 on day 3. In the logistic regression model, patients in profile 1 on day 1 transitioned to profile 3 had worse survival outcome than those continue to remain in profile 1 (OR: 20.64; 95% CI: 6.01 to 70.94; p < 0.001) and transitioned to profile 2 (OR: 8.42; 95% CI: 2.22 to 31.97; p = 0.002) on day 3.

Conclusion

The study identified three subphenotypes of CA, which was consistent on day 1 and 3 after ICU admission. Patients who transitioned to profile 3 on day 3 had significantly worse survival outcome than those remained in profile 1 or 2.

Introduction

Cardiac arrest (CA) is an important public health problem accounting for approximately 500,000 deaths annually in the Europe and the USA [1, 2]. A significant number of patients will survive the acute event and require post-resuscitation care in the intensive care unit after return of the spontaneous circulation (ROSC) [3]. The improvement in survival outcome is relatively small in spite of recent advances in post-CA care [4]. Therapeutic interventions for post-resuscitation care including neuromuscular blockade and inhaled Xenon have been explored [58]. In particular, targeted temperature management (TTM) has been shown to improve survival and neurological functions in patients with CA [911]. Exploration of heterogeneity of the study population can further improve the efficacy of these clinical trials. The heterogeneity of critical care syndromes such as acute respiratory distress syndrome (ARDS) and sepsis has been well studied and some subphenotypes of these syndromes have been identified, exhibiting distinct clinical presentations, clinical outcomes and responses to therapeutic interventions [12]. For example, Calfee and colleagues identified 3 subphenotypes of ARDS which responded differently to fluid management strategy [13, 14]. Gårdlund B and colleagues identified 6 subphenotypes of septic shock that showed distinct clinical characteristics [15]. In addition, the subphenotype transition has also been widely investigated because unraveling the transition pattern can have significant clinical and research implications [1618]. For example, subphenotype stability over time can help to design trials and/or therapeutics. Subphenotype transition is also important to the question on whether difference in clinical presentation is dependent on the timing of measurement [16].

Similarly, CA patients in the ICU also exhibit significant heterogeneity [19, 20], and subphenotypes exploration may help to identify patients who might benefit most from certain therapeutics. Our previous work has identified subphenotypes of CA using cross-sectional data on the first day of ICU entry [21]. However, it is largely unknown whether the subphenotypes are stable or subject to transitions and how could this transition inform clinical decisions. Other studies show that subphenotype transition can have significant clinical implications [17, 22]. Thus, the current study aimed to characterize the latent transition pattern of CA patients by using latent transition analysis (LTA). The differences in the mortality outcome for patients with different transition paths were also explored.

Materials and methods

Study setting and population

The study used a large critical care database called MIMIC-III (Medical Information Mart for Intensive Care [23]. Detailed introduction of the database could be found at the website: https://mimic.physionet.org/. Briefly, the MIMIC-III is a critical care database comprising deidentified patients’ data for more than 40,000 admissions who stayed in the ICUs of the Beth Israel Deaconess Medical Center. The database includes patient information such as vital sign recordings, demographics, medications, laboratory test results, imaging reports, procedures, caregiver notes, and mortality outcome. The study was conducted by utilizing anonymized database with pre-existing institutional review board (IRB) approval. The study was conducted in accordance to the REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement [24].

Subjects selection

Subjects with the diagnosis of cardiopulmonary resuscitation (ICD-9 code: 9960 and 9963), cardiac arrest (ICD-9 code: 4275) and ventricular fibrillation (ICD-9 code: 4274) were screened for potential eligibility [25]. Only the first admission was included in the analysis for patients with multiple ICU admissions. Exclusion criteria included: 1) hospital stay > 200 days; 2) patients < 18 years old; and 3) elective admissions.

Demographical and laboratory variables

Demographic data including gender, age, admission type, ethnicity, etiology for CA and ICU type were used for analysis. Physiological variables were extracted for the first and third days after ICU admission. These variables included urine output, use of vasopressors (including norepinephrine, dopamine, epinephrine and dobutamine), and the Glasgow coma score (GCS). Sequential organ failure assessment (SOFA) score on the first day was computed.

Laboratory variables such as creatinine, potassium, total bilirubin, activated partial thrombin time (aPTT), lactate, international normalized ratio (INR), creatinine, sodium, platelet and hematocrit on day 1 and 3 after ICU admission were extracted from the database. The variable associated with the greatest severity of illness was obtained for those with multiple measurements. We also extracted vital signs including heart rate, mean BP, respiratory rate and body temperature on day 1 and 3. The hospital mortality was the primary outcome, which was defined by the vital status at the time of hospital discharge. Missing values were handled by using multiple imputations [26].

Latent profile and latent transition analysis

The LTA and LPA are closely related methodology. LPA is able to identify latent subgroups of a population by clinical features. LTA extends the methodology of LPA by identifying the movement between the subgroups over time based on longitudinal data. In our study, laboratory tests and vital signs on day 1 and 3 after ICU admission were used to identify the hidden groups. Subphenotypes were identified on day 1 and day 3. The appropriate number of profiles was determined by both clinical relevance and model fit metrics. In this study, the number of profiles were determined by entropy, Bayesian information criteria (BIC), Akaike information criterion (AIC) and Vuong-Lo-Mendell-Rubin Likelihood ratio test (LRT) likelihood ratio tests. Lower values of the AIC and BIC indicates a better model fit [27]. Higher value of entropy indicates higher model fit. A p value less than 0.05 for the LRT was used to judge the superiority of n-profile model to (n-1)-profile model [28]. Furthermore, the patient proportion in each profile should be greater than 5% [29].

The LTA model estimates the latent profile models on day 1 and 3 simultaneously. The relationship of the latent classes between day 1 and 3 was also considered. The LTA model provided an estimate of profile membership on day 1 and 3, as well as the probability of profile transition. All variables used for latent profile model were also included for LTA modeling [18].

Statistical analysis

Descriptive statistics were performed in standard way. Continuous variables were expressed as median (interquartile range [IQR]) or the mean (standard deviation) as appropriate. Differences between groups were compared using analysis of variance (ANOVA) [21, 22].

An interaction term between profile on day 1 and 3 were included in a multivariable logistic regression model to investigate the effect of each transition pattern on mortality outcome. Potential confounders including age, the SOFA score, ethnicity, ICU type, mean BP and time period of admission (2008–2012 versus before 2008) were adjusted for in the model. All statistical analyses were performed using Mplus (version 7.4) and R package (version 3.4.3). A two tailed p-value < 0.05 was considered as statistical significance.

Results

Patient selection

A total of 52,963 admissions were initially identified from the MIMIC-III database. Subjects were excluded as per the exclusion criteria: 101 patients were excluded because they were younger than 18 years old; seven admissions were excluded because of LOS >200 days; and 7391 were excluded because of the elective admission. In the remaining patients, 1361 were ICU admissions due to cardiac arrest. Eight admissions were not the first ICU admission and were further excluded. A number of 504 patients were excluded because they stayed in ICU for less than 3 days. As a result, a number of 848 CA subjects were included for the final analysis (Fig 1).

Fig 1. Flowchart identification of eligible patients from the database.

Fig 1

The best number of latent profiles

LPA models with varying number of profiles were fitted and compared for their model fit. The AIC and BIC values dropped rapidly from 2 to 3-profile model (dropped by 1000). The entropy dropped remarkably from a 3-profile model to 4-profile model (from 0.962 to 0.956). The LRT did not show a significant model fit gain for the 3 and 4-profile models. Furthermore, the profile 2 and 4 contained less than 5% of patients in the 4-profile model. Collectively, the 3-profile model was selected the model with best fit metrics (Table 1).

Table 1. Choose the number of profiles on day 1.

Number of subjects in each profile (%)
Number of profiles BIC LL AIC aBIC Entropy AICC P* 1 2 3 4 5 6 7
2 119900.6 -59724.40 119582.8 119687.8 1.000 119594.5 0.2860 17(2) 831(98)
3 118928.9 -59161.00 118502.0 118643.1 0.962 118523.6 0.0464 621(73) 112(13) 115(14)
4 118561.6 -58899.81 118025.6 118202.7 0.956 118060.7 0.3778 113(13) 34(4) 696(82) 5(1)
5 117663.4 -58373.17 117018.3 117231.5 0.947 117070.8 0.3369 113(13) 29(3) 596(70) 105(12) 5(1)
6 117317.2 -58122.55 116563.1 116812.3 0.954 116637.0 0.3234 17(2) 115(14) 652(77) 5(1) 26(3) 33(4)
7 117166.5 -57969.67 116303.3 116588.6 0.944 116403.5 0.3152 26(3) 597(70) 17(2) 113(13) 33(4) 57(7) 5(1)

*The n-profile model was compared to the (n-1)-profile model and p value was reported based on the VUONG-LO-MENDELL-RUBIN likelihood ratio test.

Abbreviations: AICC: Akaike Information Criterion corrected; AIC: Akaike Information Criterion; aBIC: adjusted Bayesian information criteria; BIC: Bayesian information criteria.

On day 3, the 3-profile model was also chosen as the best model by considering all metrics (Table 2). The LRT showed that the 3-profile model was not significantly worse than the 4-profile model and entropy also indicated better model fit for 3-profile model than 4-profile model. Profile 4 in the 4-profile model contained less than 5% of the overall population (4%).

Table 2. Statistical metrics for determining the best number of profiles on day 3.

Number of subjects in each profile (%)
Number of profiles LL AIC BIC aBIC Entropy AICC P* 1 2 3 4 5 6 7
2 -56606.75 113347.5 113665.3 113452.5 0.996 113359.2 0.0162 806(95) 42(5)
3 -56103.89 112387.8 112814.6 112528.8 0.990 112409.4 0.0000 704(83) 104(12) 39(5)
4 -55811.90 111849.8 112385.8 112026.9 0.959 111884.9 0.5678 103(12) 602(71) 108(13) 35(4)
5 -55490.60 111253.2 111898.2 111466.3 0.971 111305.6 0.1982 100(12) 85(10) 609(72) 21(2) 33(4)
6 -55426.25 111170.5 111924.6 111419.7 0.853 111244.5 0.7622 24(3) 105(12) 396(47) 272(32) 32(4) 19(2)
7 -55139.43 110642.9 111506.1 110928.1 0.977 110743.0 0.8138 7(1) 32(4) 85(10) 596(70) 20(2) 95(11) 12(1)

*P value was obtained by comparing the n-profile model to the (n-1)-profile model according to the VUONG-LO-MENDELL-RUBIN likelihood ratio test.

Abbreviations: AICC: Akaike Information Criterion corrected; AIC: Akaike Information Criterion; aBIC: adjusted Bayesian information criteria; BIC: Bayesian information criteria.

Clinical features of the CA profiles

On day 1, Profile 1 accounted for the largest proportion (73%) and could be considered as the baseline subphenotype. Profile 2 (13%) was characterized by neurological injury (with a low GCS). The hallmark features of Profile 3 (14%) was multiple organ dysfunctions involving hepatic injury (high bilirubin), coagulopathy (decreased platelet count, prolonged aPTT and INR), renal injury (elevated creatinine and low urine output), lung injury (low SPO2) and circulatory failure (with elevated serum lactate and low BP).

Profile 1 was more likely to be from the coronary care unit (CCU) (34%) and profile 3 was more likely to be from Trauma Surgical ICU (TSICU) (15%). Patients in profile 3 were more likely to use vasopressors and inotropes (<0.05). The minimum GCS was significantly lower than other profiles (median: 3; IQR: 3 to 7; p < 0.001). Blood pressure was significantly lower in profile 3 than in other profiles (p<0.001). There was no statistically significant difference in mortality outcome among profiles on day 1 (Table 3).

Table 3. Baseline clinical characteristics and outcomes stratified by profiles on the first day.

Characteristics Total (n = 848) Profile 1 (n = 632) Profile 2 (n = 116) Profile 3 (n = 100) p
Age, years (IQR) 67.96(56.96,79.28) 68.64(58.59,79.76) 68.1(55.45,79.72) 64.62(51.88,76.19) 0.029
Gender, Male (%) 524(62) 388(61) 77(66) 59(59) 0.495
Etiology, n (%) 0.008
 ARF 257 (30) 175 (28) 50 (43) 32 (32)
 MI 129 (15) 99 (16) 15 (13) 15 (15)
 Others 293 (35) 234 (37) 30 (26) 29 (29)
 Sepsis 144 (17) 109 (17) 19 (16) 16 (16)
 Trauma 25 (3) 15 (2) 2 (2) 8 (8)
Ethnicity, n(%) 0.030
 ASIAN 16(2) 10(2) 6(5) 0(0)
 BLACK 69(8) 43(7) 12(10) 14(14)
 HISPANIC 30(4) 23(4) 5(4) 2(2)
 UNKNOWN 132(16) 104(16) 17(15) 11(11)
 WHITE 601(71) 452(72) 76(66) 73(73)
Admission period, n (%) < 0.001
 Before 2008 489(58) 384(61) 39(34) 66(66)
 2008 to 2012 359(43) 248(40) 77(66) 34(34)
GCS, median (IQR) 15(14,15) 15(15,15) 3(3,7) 15(15,15) < 0.001
SOFA, median (IQR) 6(4,9) 5(3,8) 9.5(8,12) 10(7,12) < 0.001
Mean MBP, median (IQR) 55(47,62) 55.83(48,62) 56(47,63) 48(32,56) < 0.001
Minimum MBP, median (IQR) 76.89(70.05,83.88) 76.64(69.61,83.58) 80.38(72.85,87.88) 74.97(70.19,82.45) 0.002
Care unit type, n (%) 0.001
 CCU 265(31) 212(34) 35(30) 18(18)
 CSRU 145(17) 102(16) 17(15) 26(26)
 MICU 270(32) 193(31) 49(42) 28(28)
 SICU 87(10) 63(10) 11(9) 13(13)
 TSICU 81(10) 62(10) 4(3) 15(15)
Use of vasoactive agents
Dopamine, n (%) 161(19) 114(18) 19(16) 28(28) 0.046
Epinephrine, n (%) 79(9) 48(8) 9(8) 22(22) < 0.001
Norepinephrine, n (%) 272(32) 166(26) 40(34) 66(66) < 0.001
Dobutamine, n (%) 37(4) 28(4) 1(1) 8(8) 0.037
MCS/ECMO, n (%) 102 (12) 77 (12) 6 (5) 19 (19) 0.008
Clinical outcomes
Hospital LOS, days (IQR) 12(7,22) 12(7,21) 12(7,24) 12.5(6.75,22) 0.844
ICU LOS, days (IQR) 7(4,13) 7(4,12) 7(4,14) 8(4,15) 0.386
Hospital mortality, n (%) 411(48) 298(47) 60(52) 53(53) 0.416

Abbreviations: ICU: intensive care unit; LOS: length of stay; UO: urine output; GCS: Glasgow coma scale; CCU: coronary artery unit; BP: blood pressure; SOFA: sequential organ failure assessment; CSRU: cardiac surgery recovery unit; SICU: surgical ICU; MICU: medical ICU; TSICU: Trauma-Neuro ICU; ECMO: Extracorporeal membrane oxygenation; ARF: acute respiratory failure; MI: myocardial infarction; MCS: mechanical circulatory support.

Interventions for the three profiles of CA

There were significant differences in the drug intervention across the three subtypes of CA. For example, profile 3 was more likely to use dopamine than profile 1 and 2. While profile 2 used more norepinephrine than profile 1, profile 1 used more dopamine than profile 2 (Table 3). Profile 3 was more likely to use circulatory support than profile 2 (19% vs. 5%; p = 0.008).

Latent transition analysis

LTA showed that three profiles could be identified at day 1 and day 3, and the results were very similar to that obtained from LPA. The entropy was 0.970. Characteristics of profiles on day 1 and 3 are shown in Fig 2. Consistent with the LPA analysis, profile 1 was the baseline subphenotype; profile 2 was characterized by neurological injury and profile 3 was characterized by multiple organ dysfunctions.

Fig 2. Clinical characteristics of the three latent profiles on day 1 and 3.

Fig 2

Z-score was normalized by subtracting each individual value by the population mean and divided by the standard deviation. The horizontal line displays the clinical characteristics. Abbreviations: INR: international normalized ratio; aPTT: activated partial thrombin time; HR: heart rate; WBC: white blood cell count; RR: respiratory rate; UO: urine output; BP: blood pressure; GCS: Glasgow Coma Scale.

As shown in Table 4, 535 (85%) patients in profile 1 on day 1 remained in the same profile on day 3. Sixty-one patients (10%) transitioned to profile 2 and 36 (6%) transitioned to profile 3, indicating deterioration of the disease. A majority of patients in profile 2 (72%) and 3 (82%) on day 1 switched to profile 1 on day 3, indicating improvement in medical condition after treatment (Table 4).

Table 4. Transition probability from day 1 to day 3.

Day 3 profiles, n (%)
Day 1 profiles, n (%) 1 2 3
1 535(85) 61(10) 36(6)
2 83(72) 30(26) 3(3)
3 82(82) 12(12) 6(6)

Note: the rows represent the profiles on day 1 after ICU admission, and the column indicates the profiles on day 3. The table shows the number of patients (n, %) transitioned on day 1 and 3.

Impact of therapeutic intervention on profile transition

The associations of medical interventions, such as vasoactive agents and circulatory support, with the transition pattern were explored by univariate analysis. We compared patients transitioned from profile 2 and 3 to profile 1 versus those did not transition to profile 1 (Table 5). The results showed that there was no significant difference between the two transition groups in terms of medications and mechanical circulatory support. Probably, the transition pattern is the intrinsic nature of the disease progression, and current study is not able to identify effective therapeutic intervention that could change the transition path.

Table 5. Comparisons between patients who transitioned from profile 2 or 3 to profile 1 versus those not transitioned to profile 1.

Variables Total (n = 216) Not transition to profile 1 (n = 51) Transition to profile 1 (n = 165) p
Age (years), Median (IQR) 66.00 (54.12, 78.10) 66.33 (55.26, 75.85) 65.44 (54.07, 78.97) 0.806
Gender, Male (%) 136 (63) 33 (65) 103 (62) 0.897
SOFA, Median (IQR) 10.00 (7.00, 12.00) 9.00 (7.00, 10.50) 10.00 (8.00, 12.00) 0.118
Dopamine use, n (%) 47 (22) 7 (14) 40 (24) 0.162
Epinephrine use, n (%) 31 (14) 7 (14) 24 (15) 1.000
Norepinephrine use, n (%) 106 (49) 21 (41) 85 (52) 0.258
Dobutamine use, n (%) 9 (4) 1 (2) 8 (5) 0.689
MCS/ECMO, n (%) 191 (88) 45 (88) 146 (88) 1.000
Etiology, n (%) 0.777
 ARF 82 (38) 20 (39) 62 (38)
 MI 30 (14) 6 (12) 24 (15)
 Others 59 (27) 12 (24) 47 (28)
 Sepsis 35 (16) 11 (22) 24 (15)
 Trauma 10 (5) 2 (4) 8 (5)

Abbreviations: SOFA: sequential organ failure assessment; ECMO: Extracorporeal membrane oxygenation; MCS: mechanical circulatory support; ARF: acute respiratory failure; MI: myocardial infarction.

Clinical outcomes of CA profiles based on LTA

There was no statistical difference in hospital mortality between the three latent profiles on day 1 after adjusting for other covariates (Table 6). In the logistic regression model incorporating interaction between profiles on day 1 and 3 (Table 7), the result showed that patients in profile 1 on day 1 transitioned to profile 3 had worse survival outcome than those remained in profile 1 (OR: 20.64; 95% CI: 6.01 to 70.94; p<0.001) and transitioned to profile 2 (OR: 8.42; 95% CI: 2.22 to 31.97; p = 0.002) on day 3. Patients remained in profile 1 showed significantly better outcome than those transitioned to profile 2 (OR: 0.41; 95% CI: 0.23 to 0.73; p = 0.002). For patients in profile 2 on day 1, patients transitioned to profile 1 showed significantly better outcome than those remained profile 2 (OR: 0.30; 95% CI: 0.12 to 0.78; p = 0.014). For patients in profile 3 on day 1, the transition patterns did not have significant impact on hospital mortality (Table 7).

Table 6. Risk factors for hospital mortality on day 1.

Features Odds Ratio Lower limit of 95% CI Upper limit of 95% CI P value
Age, with each 10-year increase 1.04 1.01 1.07 0.014
SOFA (with 1-point increase) 1.07 1.02 1.12 0.006
Ethnicity (Asia as reference)
 BLACK 1.16 0.36 3.75 0.800
 HISPANIC 0.48 0.12 1.78 0.269
 WHITE 1.03 0.35 3.04 0.952
 UNKNOWN 1.25 0.41 3.85 0.695
Profile 1 as reference
Profile 2 0.91 0.57 1.45 0.686
Profile 3 1.08 0.67 1.75 0.752
Mean MBP (with each 20-mmHg increase) 1.07 0.81 1.42 0.616
Care unit type (CCU as reference)
 TSICU 2.17 1.29 3.67 0.004
 CSRU 0.53 0.34 0.82 0.005
 MICU 2.19 1.53 3.13 < 0.001
 SICU 1.31 0.79 2.16 0.290
Admission period (before 2008 as reference) 0.79 0.59 1.07 0.126

Abbreviations: CCU: coronary artery unit; SOFA: sequential organ failure assessment; CSRU: cardiac surgery recovery unit; SICU: surgical ICU; MICU: medical ICU; TSICU: Trauma-Neuro ICU.

Table 7. Interaction between day 1 and day 3 in multivariable regression model.

Variables Odds Ratio Lower limit of 95% CI Upper limit of 95% CI P value
Age, with each 10-year increase 1.04 1.01 1.07 0.016
SOFA (with 1-point increase) 1.06 1.01 1.11 0.026
Mean MBP (with each 20-mmHg increase) 1.03 0.77 1.38 0.843
Ethnicity (Asia as reference)
 BLACK 1.54 0.47 5.08 0.474
 HISPANIC 0.54 0.13 2.14 0.380
 WHITE 1.33 0.45 3.97 0.607
 UNKNOWN 1.65 0.53 5.19 0.387
Care unit type (CCU as reference)
 CSRU 0.41 0.25 0.66 < 0.001
 SICU 1.22 0.72 2.07 0.453
 TSICU 2.24 1.32 3.85 0.003
 MICU 2.21 1.54 3.20 < 0.001
Admission period (before 2008 as reference) 0.72 0.52 0.98 0.039
Interaction between day 1 and day 3 profiles
Profile 1 on day 1
 Transition to 3 versus 1 20.64 6.01 70.94 < 0.001
 Transition to 3 versus 2 8.42 2.22 31.97 0.002
 Stay in 1 versus transition to 2 0.41 0.23 0.73 0.002
Profile 2 on day 1
 Transition to 3 versus 1 8.39 0.7 100.33 0.093
 Transition to 3 versus 2 2.54 0.19 33.52 0.480
 Transition to 1 versus 2 0.3 0.12 0.78 0.014
Profile 3 on day 1
 Stay in 3 versus transition to 1 3.4 0.37 31.21 0.279
 Stay in 3 versus transition to 2 2.36 0.19 28.84 0.501
 Transition to 1 versus 2 0.69 0.19 2.6 0.588

Abbreviations: CCU: coronary artery unit; MICU: medical ICU; SOFA: sequential organ failure assessment; CSRU: cardiac surgery recovery unit; SICU: surgical ICU; TSICU: Trauma-Neuro ICU.

Discussion

This study identified three profiles of CA patients based on a large critical care database, and the three profiles were consistent on day 1 and day 3 by using LPA. Consistently, the LTA also confirmed the existence of the three subphenotypes. The three subphenotypes were: Profile 1 (73%) was characterized by the largest proportion of all CA patients and could be considered as the baseline subphenotype; Profile 2 (13%) was characterized by brain injury with a low GCS; and Profile 3 (14%) was featured by multiple organ dysfunctions. The same three profiles were identified on day 3 and there were transitions among these profiles. A substantial number of patients in profile 2 (72%) and 3 (82%) on day 1 transitioned to profile 1, suggesting that many patients recovered from multiple organ dysfunction and neurological injury from acute phase after treatment. Most patients in profile 1 remained assigned to profile 1 on day 3 (85%), but a minority, 10% and 6% showed deterioration that transitioned to profile 2 and 3, respectively. Not surprisingly, the mortality outcome was significantly better for patients transitioned to profile 1 on day 3 than those transitioned or remained in profile 2 or 3. The profiles of CA identified by the big data analytics are consistent with the pathology of post-cardiac arrest syndrome. The novelty of the study was that we further quantitatively described the epidemiology of the profiles as well as the transitions among these profiles based on a large critical care database. We also quantitatively showed that patients with different transition trajectories presented different clinical outcomes. The transition pattern of post-cardiac arrest syndrome is helpful for risk stratification, which is important for medical resource allocation and decision making. Furthermore, transition pattern might be indicative of medical interventions that can help to direct treatment, although current study failed to identify any difference in interventions across different transition patterns.

An interesting finding in the study was that patients with multiple organ dysfunction and those with neurological injury were categorized into different subgroups. This finding indicates that these patients should be managed differently. Also, the results have implications for the design of clinical trials. For instance, clinical trials designed to investigate agents or interventions with neurological protective property should be performed in profile 2. In a recent study, Nishikimi M and colleagues showed that the effect of mild therapeutic hypothermia was different depending on the presence or absence of hypoxic encephalopathy [30]. The effects of organ support interventions such as mechanical circulatory support (MCS) and ECMO can be investigated in profile 3 patients. The study highlighted the importance of individualized treatment for post-resuscitation syndrome. Similarly, trials aiming to investigate management of multiple organ dysfunctions should target patients with profile 3. Profile 3 patients are characterized by circulatory shock and multiple organ failure involving liver, respiratory system, kidney and coagulation. The global ischemia during cardiac arrest leads to rapid release of toxic enzymes and free radicals into circulation, which in turn causes microvascular and metabolic abnormalities of varying degrees [31]. These metabolic disorders were reflected by the deranged laboratory variables associated with multiple organs systems. In our study, the routinely measured laboratory variables and vital signs were used to identify subphenotypes, making our results generalizable to other institutions. Subphenotypes of a disease are usually explored by using genomic information or biomarkers that were not routinely obtained in clinical practice [32, 33]. Although these studies provide more in-depth insights into the underlying pathophysiology of each distinct subphenotype, their clinical utility is limited due to unavailability of these novel biomarkers or transcriptomics. In this regard, the utilization of information collected in the electronic healthcare records was a strength of the present study.

The transition probability between subphenotyes is an interesting finding in our study. It was noted that most patients in profile 2 (neurological injury) and 3 (multiple organ failure) transitioned to profile 1 (baseline group) after 3 days treatment. Furthermore, patients transitioned to profile 1 showed significantly better survival outcome than those remained in profile 2 or 3. The transition process may reflect treatment strategies used to correct metabolic disorders. For example, the goal directed bundle including a target of blood pressure, lactate clearance and urine output was initiated for patients with circulatory shock [34]. In the study, we found that the profile 3 had significantly greater proportions of the patients on vasopressors and inotropes. There was a substantial number of patients (n = 12; 12%) who transitioned from profile 3 (metabolic disorder) to profile 2 (neurological injury). This indicated the uncontrolled metabolic derangement caused by the ischemia/reperfusion injury would finally lead to brain injury. Neurological outcome is an important component of successful post-resuscitation care. Probability, the brain injury may occur in two stages. Hypoperfusion of the brain directly caused by CA explains brain injury during the first stage, and prolonged metabolic derangement during the post-resuscitation care is responsible for the second stage brain injury.

Several limitations of the study must be acknowledged. First, it is well acknowledged that cardiac arrest may be followed by brain injury, systemic hypo-perfusion, and multiple organ dysfunction. However, there is no direct annotation for the reasons of CA in the database. Thus, we included coexisting diagnosis as possible reasons of the CA. Furthermore, possible reasons for CA can also be deduced by the type of ICU. For example, the possible reason of CA in CCU is most probably myocardial infarction or arrythmia, and MICU patients may suffer from multiple organ failure. Second, the study failed to find any interventions that were associated with transition patterns. Most probably, the fact that there was no difference in the medications between the patients that transitioned versus those that did not transition could reflect an intrinsic nature of the disease and lack of identifiable interventions that were associated with transitions. Other reasons are that the number of interventions being explored is limited and the study may not have enough power to detect some small effect sizes. Third, our study showed that patients who transitioned from profile 3 to profile 1 did not demonstrate an impact on mortality compared to those who remained in profile 3, which is counterintuitive as judged by clinical expertise. The result showed a trend that patients remained in profile 3 had a 3-fold increase in mortality but the statistical significance was not reached, which could be explained by the small sample size in profile 3 in the study.

In conclusion, our study identified three subphenotypes of CA, which were consistent on day 1 and 3 after ICU admission. There was a substantial transition between these subphenotypes. While most patients experienced recovery after initial therapy especially the ones who transitioned from profile 2 or 3 to profile 1; a minority of patients showed deterioration who transitioned from profile 1 to profile 2 or 3. We would like to suggest that clinical trials should be designed by targeting the patient population to specific subphenotypes depending on explored interventions.

Data Availability

Data cannot be shared publicly because the data are owned by a third party and authors do not have permission to share the data. Data are available from the Beth Israel Deaconess Medical Center Institutional Data Access (via https://physionet.org/content/mimiciii/1.4/) for researchers who meet the criteria for access to confidential data.

Funding Statement

Z.Z. received funding from Yilu “Gexin” - Fluid Therapy Research Fund Project (YLGX-ZZ-2020005), Health Science and Technology Plan of Zhejiang Province (2021KY745), the Key Laboratory of Tropical Cardiovascular Diseases Research of Hainan Province (Grant.KLTCDR-202001) and Key Laboratory of Emergency and Trauma (Hainan Medical University), Ministry of Education (Grant.KLET-202017). Y.H. received funding from Key Research & Development project of Zhejiang Province (2021C03071). The study was funded by clinical research foundation of Zhejiang Medical Association (2019ZYC-A87).

References

  • 1.Atwood C, Eisenberg MS, Herlitz J, Rea TD. Incidence of EMS-treated out-of-hospital cardiac arrest in Europe. Resuscitation. 2005;67: 75–80. 10.1016/j.resuscitation.2005.03.021 [DOI] [PubMed] [Google Scholar]
  • 2.Writing Group Members, Mozaffarian D, Benjamin EJ, Gi AS, Arnett DK, Blaha MJ, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133: e38–360. 10.1161/CIR.0000000000000350 [DOI] [PubMed] [Google Scholar]
  • 3.Chan PS, McNally B, Tang F, Kellermann A, CARES Surveillance Group. Recent trends in survival from out-of-hospital cardiac arrest in the United States. Circulation. Lippincott Williams & Wilkins Hagerstown, MD; 2014;130: 1876–1882. 10.1161/CIRCULATIONAHA.114.009711 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Sasson C, Rogers MAM, Dahl J, Kellermann AL. Predictors of survival from out-of-hospital cardiac arrest: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. Lippincott Williams & Wilkins; 2010;3: 63–81. 10.1161/CIRCOUTCOMES.109.889576 [DOI] [PubMed] [Google Scholar]
  • 5.Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, et al. Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med. Massachusetts Medical Society; 2013;369: 2197–2206. 10.1056/NEJMoa1310519 [DOI] [PubMed] [Google Scholar]
  • 6.Lilja G, Nielsen N, Friberg H, Horn J, Kjaergaard J, Nilsson F, et al. Cognitive function in survivors of out-of-hospital cardiac arrest after target temperature management at 33°C versus 36°C. Circulation. Lippincott Williams & Wilkins Hagerstown, MD; 2015;131: 1340–1349. 10.1161/CIRCULATIONAHA.114.014414 [DOI] [PubMed] [Google Scholar]
  • 7.Arola O, Saraste A, Laitio R, Airaksinen J, Hynninen M, Bäcklund M, et al. Inhaled Xenon Attenuates Myocardial Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest: The Xe-Hypotheca Trial. J Am Coll Cardiol. 2017;70: 2652–2660. 10.1016/j.jacc.2017.09.1088 [DOI] [PubMed] [Google Scholar]
  • 8.Stöckl M, Testori C, Sterz F, Holzer M, Weiser C, Schober A, et al. Continuous versus intermittent neuromuscular blockade in patients during targeted temperature management after resuscitation from cardiac arrest-A randomized, double blinded, double dummy, clinical trial. Resuscitation. 2017;120: 14–19. 10.1016/j.resuscitation.2017.08.238 [DOI] [PubMed] [Google Scholar]
  • 9.Donnino MW, Andersen LW, Berg KM, Reynolds JC, Nolan JP, Morley PT, et al. Temperature Management After Cardiac Arrest: An Advisory Statement by the Advanced Life Support Task Force of the International Liaison Committee on Resuscitation and the American Heart Association Emergency Cardiovascular Care Committee and the Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Circulation. Lippincott Williams & Wilkins Hagerstown, MD; 2015;132: 2448–2456. 10.1161/CIR.0000000000000313 [DOI] [PubMed] [Google Scholar]
  • 10.Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. Massachusetts Medical Society; 2002;346: 549–556. 10.1056/NEJMoa012689 [DOI] [PubMed] [Google Scholar]
  • 11.Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. Massachusetts Medical Society; 2002;346: 557–563. 10.1056/NEJMoa003289 [DOI] [PubMed] [Google Scholar]
  • 12.Zhang Z, Navarese EP, Zheng B, Meng Q, Liu N, Ge H, et al. Analytics with artificial intelligence to advance the treatment of acute respiratory distress syndrome. J Evid Based Med. John Wiley & Sons, Ltd; 2020;13: 301–312. 10.1111/jebm.12418 [DOI] [PubMed] [Google Scholar]
  • 13.Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2: 611–620. 10.1016/S2213-2600(14)70097-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Famous KR, Delucchi K, Ware LB, Kangelaris KN, Liu KD, Thompson BT, et al. Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy. Am J Respir Crit Care Med. American Thoracic Society; 2017;195: 331–338. 10.1164/rccm.201603-0645OC [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Gårdlund B, Dmitrieva NO, Pieper CF, Finfer S, Marshall JC, Taylor Thompson B. Six subphenotypes in septic shock: Latent class analysis of the PROWESS Shock study. J Crit Care. 2018;47: 70–79. 10.1016/j.jcrc.2018.06.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Delucchi K, Famous KR, Ware LB, Parsons PE, Thompson BT, Calfee CS, et al. Stability of ARDS subphenotypes over time in two randomised controlled trials. Thorax. 2018;73: 439–445. 10.1136/thoraxjnl-2017-211090 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Ribeiro AGA, Martins RFM, Vissoci JRN, da Silva NC, Rocha TAH, Queiroz RC de S, et al. Progress and challenges in potential access to oral health primary care services in Brazil: A population-based panel study with latent transition analysis. PLoS ONE. Public Library of Science; 2021;16: e0247101. 10.1371/journal.pone.0247101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Collins LM, Lanza ST. Latent Class and Latent Transition Analysis: With Applications in the Social, Behavioral, and Health Sciences. Latent Class and Latent Transition Analysis: With Applications in the Social, Behavioral, and Health Sciences. Hoboken, NJ, USA: John Wiley & Sons, Inc; 2010. pp. 1–295. 10.1002/9780470567333 [DOI] [Google Scholar]
  • 19.Varvarousis D, Varvarousi G, Iacovidou N, D’Aloja E, Gulati A, Xanthos T. The pathophysiologies of asphyxial vs dysrhythmic cardiac arrest: implications for resuscitation and post-event management. Am J Emerg Med. 2015;33: 1297–1304. 10.1016/j.ajem.2015.06.066 [DOI] [PubMed] [Google Scholar]
  • 20.Varvarousis D, Xanthos T, Ferino G, Noto A, Iacovidou N, Mura M, et al. Metabolomics profiling reveals different patterns in an animal model of asphyxial and dysrhythmic cardiac arrest. Sci Rep. Nature Publishing Group; 2017;7: 16575. 10.1038/s41598-017-16857-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Zhang Z, Yao M, Ho KM, Hong Y. Subphenotypes of Cardiac Arrest Patients Admitted to Intensive Care Unit: a latent profile analysis of a large critical care database. Sci Rep. Nature Publishing Group; 2019;9: 13644–8. 10.1038/s41598-019-50178-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Yuan Y, Lapane KL, Rothschild AJ, Ulbricht CM. Changes in depressive symptoms and cognitive impairment in older long-stay nursing home residents in the USA: a latent transition analysis. Aging Ment Health. Routledge; 2020;: 1–10. 10.1080/13607863.2020.1849021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Johnson AEW, Pollard TJ, Shen L, Lehman L-WH, Feng M, Ghassemi M, et al. MIMIC-III, a freely accessible critical care database. Sci Data. Nature Publishing Group; 2016;3: 160035. 10.1038/sdata.2016.35 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015;12: e1001885. 10.1371/journal.pmed.1001885 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Vallabhajosyula S, Jentzer JC, Zack CJ. Cardiac Arrest Definition Using Administrative Codes and Outcomes in Acute Myocardial Infarction. Mayo Clin Proc. 2020;95: 611–613. 10.1016/j.mayocp.2019.12.007 [DOI] [PubMed] [Google Scholar]
  • 26.Zhang Z. Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med. 2016;4: 30. 10.3978/j.issn.2305-5839.2015.12.63 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Pastor DA, Barron KE, Miller BJ, Davis SL. A latent profile analysis of college students’ achievement goal orientation. Contemporary Educational Psychology. 2007;32: 8–47. 10.1016/j.cedpsych.2006.10.003 [DOI] [Google Scholar]
  • 28.Lo Y. Testing the number of components in a normal mixture. Biometrika. 2001;88: 767–778. 10.1093/biomet/88.3.767 [DOI] [Google Scholar]
  • 29.Nasserinejad K, van Rosmalen J, de Kort W, Lesaffre E. Comparison of Criteria for Choosing the Number of Classes in Bayesian Finite Mixture Models. Tran US, editor. PLoS ONE. Public Library of Science; 2017;12: e0168838. 10.1371/journal.pone.0168838 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Nishikimi M, Ogura T, Nishida K, Takahashi K, Fukaya K, Liu K, et al. Differential effect of mild therapeutic hypothermia depending on the findings of hypoxic encephalopathy on early CT images in patients with post-cardiac arrest syndrome. Resuscitation. 2018;128: 11–15. 10.1016/j.resuscitation.2018.04.029 [DOI] [PubMed] [Google Scholar]
  • 31.Hassager C, Nagao K, Hildick-Smith D. Out-of-hospital cardiac arrest: in-hospital intervention strategies. Lancet. 2018;391: 989–998. 10.1016/S0140-6736(18)30315-5 [DOI] [PubMed] [Google Scholar]
  • 32.Courcoul A, Moyen J-L, Brugère L, Faye S, Hénault S, Gares H, et al. Estimation of sensitivity and specificity of bacteriology, histopathology and PCR for the confirmatory diagnosis of bovine tuberculosis using latent class analysis. Kaltenboeck B, editor. PLoS ONE. 2014;9: e90334. 10.1371/journal.pone.0090334 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Beijers L, Wardenaar KJ, Bosker FJ, Lamers F, van Grootheest G, de Boer MK, et al. Biomarker-based subtyping of depression and anxiety disorders using Latent Class Analysis. A NESDA study. Psychol Med. 2018;77: 1–11. 10.1017/S0033291718001307 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Callaway CW, Donnino MW, Fink EL, Geocadin RG, Golan E, Kern KB, et al. Part 8: Post-Cardiac Arrest Care: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. 2015. pp. S465–82. 10.1161/CIR.0000000000000262 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Saraschandra Vallabhajosyula

16 Mar 2021

PONE-D-20-40279

Stability of Subphenotypes of Cardiac Arrest Patients Admitted to Intensive Care Unit: a latent transition analysis of a large critical care database

PLOS ONE

Dear Dr. Zhang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 23 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Saraschandra Vallabhajosyula, MD MSc

Academic Editor

PLOS ONE

Additional Editor Comments:

I agree with all the comments from the Reviewers. Specifically, Reviewer 3 who mentions overlap with two prior publications - This study with the different subphenotypes has been published earlier, the previous study which has been published in Nature is entitled: Subphenotypes of Cardiac Arrest Patients Admitted to Intensive Care Unit: a latent profile analysis of a large critical care database, link to the article is attached below: https://doi.org/10.1038/s41598-019-50178-0. Most of the information in the above mentioned study has been almost copied verbatim in the present study entitled: Stability of Subphenotypes of Cardiac Arrest Patients Admitted to Intensive Care Unit: a latent transition analysis of a large critical care database. The only additional information in this study in the cross over of subphenotypes and it's effect on mortality on day 3 of hospitalization.

I suggest the authors consider addressing this in great detail to distinguish it from existing papers.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Funding Section of your manuscript:

"Z.Z. received funding from The public welfare research project of Zhejiang province

(LGF18H150005) and Scientific research project of Zhejiang Education Commission

(Y201737841);"

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

5. Thank you for submitting the above manuscript to PLOS ONE. During our internal evaluation of the manuscript, we found significant text overlap between your submission and the following previously published works, some of which you are an author.

https://www.nature.com/articles/s41598-019-50178-0

We would like to make you aware that copying extracts from previous publications, especially outside the methods section, word-for-word is unacceptable. In addition, the reproduction of text from published reports has implications for the copyright that may apply to the publications.

Please revise the manuscript to rephrase the duplicated text, cite your sources, and provide details as to how the current manuscript advances on previous work. Please note that further consideration is dependent on the submission of a manuscript that addresses these concerns about the overlap in text with published work.

We will carefully review your manuscript upon resubmission, so please ensure that your revision is thorough.

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors of the present study present a well thought out analysis of a secondary database to evaluate sub-phenotypes of cardiac arrest. The authors conclude that the study identified three sub-phenotypes of cardiac arrest which were consistent on day 1 and day 3 after ICU admission. What is unclear is the importance of the study findings. The three profiles identified by the authors (a baseline profile, one with neurologic injury and the third with multiorgan dysfunction) are not new and are recognized to be part of the pathology of post-cardiac arrest syndrome.

It is well acknowledged that cardiac arrest may be followed by brain injury, systemic hypo-perfusion, and multiple organ dysfunction. Therefore, if anything the three profiles identified by the authors indicate patients at varying stages of disease post cardiac arrest. And this sequence of events entirely depends on the timing of arrest, management strategy and importantly underlying pathology.

Can the authors provide any information on the cause of cardiac arrest, timing of arrest along with if and how these patients were managed? Providing analytical results without clinical picture does not add anything to aid in decision making for these patients.

The authors go on to compare outcomes of the three identified profiles. As previously mentioned, it appears these patients are at different stages of the disease and without knowing granular information on the extent and causes of disease, these outcome comparisons are not of value.

It is understandable that sicker patients respond and get better or worse depending on the timeliness, efficacy and other intrinsic factors of treatment strategies. Do we need an analysis to establish this especially with a dynamic condition like post-cardiac arrest pathology?

A more clear presentation of the clinical profiles along with management of these patients may be of value to the reader.

Reviewer #2: I had the chance to review the manuscript “Stability of Subphenotypes of Cardiac Arrest Patients Admitted to Intensive Care Unit: a latent transition analysis of a large critical care database”. The manuscript is well-written, scientifically sound and targets an interesting topic. The authors do a great job in highlighting subgroups that may benefit from individualized management strategies. I have a few comments for the authors’ consideration.

Major comments

1. Inclusion of mechanical circulatory support (MCS) and ECMO as variables for the LTA and LPA would be extremely valuable. It would also be instructive for the readers if the use of MCS and ECMO could be included in Table-3.

2. I would recommend using multiple ICD-9 codes for CA rather than just one code (427.5). ICD-9-CM codes identify CA with varying accuracy and outcomes of CA vary depending on the administrative definition used. (Please refer to Vallabhajosyula et al. Mayo Clin Proc. 2020 doi: 10.1016/j.mayocp.2019.12.007).

3. Include a section on the limitations of the study.

4. If the database allows, stratifying Cardiac arrest by the etiology would enrich the paper. The clinical course, management, and outcomes of CA secondary to different etiologies (ie. MI, Sepsis, ARDS etc ) are quite distinct and targeting individual pathologies would be of benefit.

5. In the discussion the authors mention that the transition process may reflect the treatment strategies used. Would it be possible to assess the different treatment strategies used in patients who transitioned from profile 2 and profile 3 to profile 1 compared to those who remained in their respective profiles?

6. The authors discuss the impact of using the profiling of cardiac arrest patients for clinical trials. It would be informative for readers if they could discuss a proposed clinical approach / management strategy to the 3 distinct profiles encountered on day 1.

Minor comments

1. Consider discussing why the patients who transitioned from profile 3 to profile 1 did not demonstrate an impact on mortality compared to those who remained in profile 3.

2. Line 6 in the Introduction section tends to suggest that TTM has only shown success only in animal studies and not human studies which is not accurate as several studies demonstrated that TTM has improved survival and neurological function in patients with CA. This could be rephrased. (Please refer to the following doi:10.1161/CIR.0000000000000313; doi:10.1056/NEJMoa012689; doi:10.1056/NEJMoa003289).

3. Page 18 Line 23. “In this study, we found that the profile 2 had significantly greater…” Shouldn’t it be profile 3.

4. Line 9 of the discussion should be ‘transitioned to profile 1’ instead of ‘profile 3’.

5. The last sentence of the first paragraph in the discussion section needs to be rephrased.

Reviewer #3: In this original manuscript entitled,” Stability of Subphenotypes of Cardiac Arrest Patients Admitted to Intensive Care Unit:

a latent transition analysis of a large critical care database”,. This is a retrospective US based critical care database study that classifies cardiac arrest into three subphenotypes using the latent transition analysis and evaluates the stability of the three subphenotypes and effects on the ICU mortality outcomes. 848 patients were included and the study demonstrates that patients who transitioned to subphenotype 3 on day 3 of hospitalization had worse survival outcomes.

major comments

1. The introduction and discussion can be more focused on the implications of the stability and transition of subphenotypes

2. This study is similar to your previous study entitled ' Subphenotypes of Cardiac Arrest Patients Admitted to Intensive Care Unit: a latent profile analysis of a large critical care database. would recommend you mention the previous study and highlight the findings of the new study.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Dhiran Verghese

Reviewer #3: Yes: Aditi Shankar

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 May 27;16(5):e0252318. doi: 10.1371/journal.pone.0252318.r002

Author response to Decision Letter 0


22 Mar 2021

To Dr. Saraschandra Vallabhajosyula

Academic Editor

PLOS ONE

Dear Dr. Vallabhajosyula

We thank you and reviewers for the generous comments on the manuscript and have revised the manuscript to address these concerns. Here we enclose our point-by-point responses to the comments raised by the reviewers and editors. We hope our responses and revisions made to the manuscript can address these concerns. We are looking forward to your positive response.

Yours sincerely,

Zhongheng Zhang, MD

Department of Emergency Medicine,

Sir Run Run Shaw Hospital,

Zhejiang University School of Medicine,

Hangzhou,

310016,

China.

Email: zh_zhang1984@zju.edu.cn

Additional Editor Comments:

REVIEWER COMMENT: I agree with all the comments from the Reviewers. Specifically, Reviewer 3 who mentions overlap with two prior publications - This study with the different subphenotypes has been published earlier, the previous study which has been published in Nature is entitled: Subphenotypes of Cardiac Arrest Patients Admitted to Intensive Care Unit: a latent profile analysis of a large critical care database, link to the article is attached below: https://doi.org/10.1038/s41598-019-50178-0. Most of the information in the above mentioned study has been almost copied verbatim in the present study entitled: Stability of Subphenotypes of Cardiac Arrest Patients Admitted to Intensive Care Unit: a latent transition analysis of a large critical care database. The only additional information in this study in the cross over of subphenotypes and it's effect on mortality on day 3 of hospitalization.

I suggest the authors consider addressing this in great detail to distinguish it from existing papers.

RESPONSE: Many thanks for the constructive suggestions and we thoroughly revised the manuscript to avoid verbatim. Futhermore, we added some lines in the introduction section to describe our previous work and how can the present study add to the existing literature.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure): Our previous work has identified subphenotypes of CA using cross-sectional data on the first day of ICU entry [21]. However, it is largely unknown whether the subphenotypes are stable or subject to transitions and how this transition can impact clinical outcomes. Other studies show that subphenotype transition can have significant clinical implications [17,22]. Thus, the current study aimed to characterize the latent transition pattern of CA patients by using latent transition analysis (LTA). The differences in the mortality outcome for patients with different transition paths were also explored.

MANUSCRIPT LOCATION: P3 L24

Reviewer #1:

REVIEWER COMMENT: The authors of the present study present a well thought out analysis of a secondary database to evaluate sub-phenotypes of cardiac arrest. The authors conclude that the study identified three sub-phenotypes of cardiac arrest which were consistent on day 1 and day 3 after ICU admission. What is unclear is the importance of the study findings. The three profiles identified by the authors (a baseline profile, one with neurologic injury and the third with multiorgan dysfunction) are not new and are recognized to be part of the pathology of post-cardiac arrest syndrome.

RESPONSE: We are grateful to the reviewer for this insightful comments. We agree with the reviewer for that the subphenotypes identified were consistent with the pathology of post-cardiac arrest syndrome. However, our study utilized big EHR data and analytics to support the pathology of post-cardiac arrest syndrome, making it more evidence based. Furthermore, we showed that these subphenotypes had important clinical implications for prognosis. We revised the manuscript in the discussion section to incorporate the important interpretation provided by the reviewer.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure): The profiles of CA identified by the big data analytics are consistent with the pathology of post-cardiac arrest syndrome. The novelty of the study is that we further quantitatively described the epidemiology of the profiles as well as the transitions among these profiles based on a large critical care database. We also quantitatively show that patients with different transition trajectories present different clinical outcomes.

MANUSCRIPT LOCATION: P17 L15

REVIEWER COMMENT: It is well acknowledged that cardiac arrest may be followed by brain injury, systemic hypo-perfusion, and multiple organ dysfunction. Therefore, if anything the three profiles identified by the authors indicate patients at varying stages of disease post cardiac arrest. And this sequence of events entirely depends on the timing of arrest, management strategy and importantly underlying pathology.

RESPONSE: we fully agree with the reviewer for the constructive comments. We added possible reasons for CA in the revision according to co-existing diagnosis. In the database, there is no direct annotation to the cardiac arrest reasons; thus we also use the information of the type of ICU to deduce possible reasons for CA. we also added this point as a limitation in the revision.

Some drug interventions were also added to the table to implicate some difference in management between subtypes.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure):

Table 3

Variables Total (n=848) Profile 1 (n=632) Profile 2 (n=116) Profile 3 (n=100) p

Etiology, n (%) 0.008

ARF 257 (30) 175 (28) 50 (43) 32 (32)

MI 129 (15) 99 (16) 15 (13) 15 (15)

Others 293 (35) 234 (37) 30 (26) 29 (29)

Sepsis 144 (17) 109 (17) 19 (16) 16 (16)

Trauma 25 ( 3) 15 (2) 2 (2) 8 (8)

Type of care unit, n(%) 0.001

CCU 265(31) 212(34) 35(30) 18(18)

CSRU 145(17) 102(16) 17(15) 26(26)

MICU 270(32) 193(31) 49(42) 28(28)

SICU 87(10) 63(10) 11(9) 13(13)

TSICU 81(10) 62(10) 4(3) 15(15)

Dopamine, n(%) 161(19) 114(18) 19(16) 28(28) 0.046

Epinephrine, n(%) 79(9) 48(8) 9(8) 22(22) 0.000

Norepinephrine, n(%) 272(32) 166(26) 40(34) 66(66) 0.000

Dobutamine, n(%) 37(4) 28(4) 1(1) 8(8) 0.037

Abbreviations: CCU: coronary artery unit; CSRU: cardiac surgery recovery unit; MICU: medical ICU; SICU: surgical ICU; TSICU: Trauma-Neuro ICU; ARF: acute respiratory failure; MI: myocardial infarction.

First, it is well acknowledged that cardiac arrest may be followed by brain injury, systemic hypo-perfusion, and multiple organ dysfunction. However, there is no direct annotation for the reasons of CA in the database. Thus, we included coexisting diagnosis as possible reasons of the CA. Furthermore, possible reasons for CA can also be deduced by the type of ICU. For example, the possible reason of CA in CCU is most probably myocardial infarction or arrythmia, and MICU patients may suffer from multiple organ failure.

MANUSCRIPT LOCATION: Table 3. P19 L11.

REVIEWER COMMENT: Can the authors provide any information on the cause of cardiac arrest, timing of arrest along with if and how these patients were managed? Providing analytical results without clinical picture does not add anything to aid in decision making for these patients.

RESPONSE: we fully agree with the reviewer on this point that analytical results without clinical picture does not add anything to aid in decision making for these patients. However,there is no direct annotation of the reasons for CA events in the database. We added co-existing diagnosis as possible reasons for the CA. We also reported the type of ICU for possible reasons of CA. For example, the possible reason of CA in CCU is most probably myocardial infarction or arrythmia, and MICU patients may suffer from multiple organ failure. We added vasopressors and mechanical circulatory support as the intervention to the results as this information is well recorded in the database.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure):

Table 3

Variables Total (n=848) Profile 1 (n=632) Profile 2 (n=116) Profile 3 (n=100) p

Etiology, n (%) 0.008

ARF 257 (30) 175 (28) 50 (43) 32 (32)

MI 129 (15) 99 (16) 15 (13) 15 (15)

Others 293 (35) 234 (37) 30 (26) 29 (29)

Sepsis 144 (17) 109 (17) 19 (16) 16 (16)

Trauma 25 ( 3) 15 (2) 2 (2) 8 (8)

Type of care unit, n(%) 0.001

CCU 265(31) 212(34) 35(30) 18(18)

CSRU 145(17) 102(16) 17(15) 26(26)

MICU 270(32) 193(31) 49(42) 28(28)

SICU 87(10) 63(10) 11(9) 13(13)

TSICU 81(10) 62(10) 4(3) 15(15)

Dopamine, n(%) 161(19) 114(18) 19(16) 28(28) 0.046

Epinephrine, n(%) 79(9) 48(8) 9(8) 22(22) 0.000

Norepinephrine, n(%) 272(32) 166(26) 40(34) 66(66) 0.000

Dobutamine, n(%) 37(4) 28(4) 1(1) 8(8) 0.037

MCS/ECMO, n (%) 102 (12) 77 (12) 6 (5) 19 (19) 0.008

Abbreviations: CCU: coronary artery unit; CSRU: cardiac surgery recovery unit; MICU: medical ICU; SICU: surgical ICU; TSICU: Trauma-Neuro ICU.

First, it is well acknowledged that cardiac arrest may be followed by brain injury, systemic hypo-perfusion, and multiple organ dysfunction. However, there is no direct annotation for the reasons of CA in the database. Thus, we included coexisting diagnosis as possible reasons of the CA. Furthermore, possible reasons for CA can also be deduced by the type of ICU. For example, the possible reason of CA in CCU is most probably myocardial infarction or arrythmia, and MICU patients may suffer from multiple organ failure.

MANUSCRIPT LOCATION: Table 3. P19 L11.

REVIEWER COMMENT: The authors go on to compare outcomes of the three identified profiles. As previously mentioned, it appears these patients are at different stages of the disease and without knowing granular information on the extent and causes of disease, these outcome comparisons are not of value.

RESPONSE: In line with previous comments, we added the type of ICU/etiology of CA and some drug/mechanical support interventions in the result section. A new section with the subtitle “Interventions for the three profiles of CA” was added in this round of revision.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure):

Interventions for the three profiles of CA

There were significant differences in the drug intervention across the three subtypes of CA. For example, profile 3 was more likely to use dopamine than profile 1 and 2. While profile 2 used more norepinephrine than profile 1, profile 1 used more dopamine than profile 2 (Table 3). Profile 3 was more likely to use circulatory support than profile 2 (19% vs. 5%; p = 0.008).

MANUSCRIPT LOCATION: Table 3; P11 L4

REVIEWER COMMENT: It is understandable that sicker patients respond and get better or worse depending on the timeliness, efficacy and other intrinsic factors of treatment strategies. Do we need an analysis to establish this especially with a dynamic condition like post-cardiac arrest pathology?

RESPONSE: We are sorry for not making the rationale of the study clear and straightforward in the first version. We added some lines in the introduction in this round of revision to clarify this point. The rationale for this study is described in the introduction.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure): Our previous work has identified subphenotypes of CA using cross-sectional data on the first day of ICU entry [21]. However, it is largely unknown whether the subphenotypes are stable or subject to transitions and how this transition can impact clinical outcomes. Other studies show that subphenotype transition can have significant clinical implications [17,22]. Thus, the current study aimed to characterize the latent transition pattern of CA patients by using latent transition analysis (LTA). The differences in the mortality outcome for patients with different transition paths were also explored.

MANUSCRIPT LOCATION: P3 L24

REVIEWER COMMENT: A more clear presentation of the clinical profiles along with management of these patients may be of value to the reader.

RESPONSE: We fully agree with the reviewer in this point. In the revision, we added some more sections to show the medication and clinical difference between the clinical profiles.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure):

Table 3

Variables Total (n=848) Profile 1 (n=632) Profile 2 (n=116) Profile 3 (n=100) p

Type of care unit, n(%) 0.001

CCU 265(31) 212(34) 35(30) 18(18)

CSRU 145(17) 102(16) 17(15) 26(26)

MICU 270(32) 193(31) 49(42) 28(28)

SICU 87(10) 63(10) 11(9) 13(13)

TSICU 81(10) 62(10) 4(3) 15(15)

Dopamine, n(%) 161(19) 114(18) 19(16) 28(28) 0.046

Epinephrine, n(%) 79(9) 48(8) 9(8) 22(22) 0.000

Norepinephrine, n(%) 272(32) 166(26) 40(34) 66(66) 0.000

Dobutamine, n(%) 37(4) 28(4) 1(1) 8(8) 0.037

MCS/ECMO, n (%) 102 (12) 77 (12) 6 (5) 19 (19) 0.008

Abbreviations: CCU: coronary artery unit; CSRU: cardiac surgery recovery unit; MICU: medical ICU; SICU: surgical ICU; TSICU: Trauma-Neuro ICU; MCS: mechanical circulatory support; ECMO: Extracorporeal membrane oxygenation.

Interventions for the three profiles of CA

There were significant differences in the drug intervention across the three subtypes of CA. For example, profile 3 was more likely to use dopamine than profile 1 and 2. While profile 2 used more norepinephrine than profile 1, profile 1 used more dopamine than profile 2 (Table 3). Profile 3 was more likely to use circulatory support than profile 2 (19% vs. 5%; p = 0.008).

MANUSCRIPT LOCATION: Table 3; P11 L4

Reviewer #2:

REVIEWER COMMENT: I had the chance to review the manuscript “Stability of Subphenotypes of Cardiac Arrest Patients Admitted to Intensive Care Unit: a latent transition analysis of a large critical care database”. The manuscript is well-written, scientifically sound and targets an interesting topic. The authors do a great job in highlighting subgroups that may benefit from individualized management strategies. I have a few comments for the authors’ consideration.

RESPONSE: Thank you for the insightful comments. We have revised the manuscrupt with point-by-point responses to each question.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure): None

MANUSCRIPT LOCATION: None

Major comments

REVIEWER COMMENT: 1. Inclusion of mechanical circulatory support (MCS) and ECMO as variables for the LTA and LPA would be extremely valuable. It would also be instructive for the readers if the use of MCS and ECMO could be included in Table-3.

RESPONSE: we fully agree with the reviewer on this point and added such information in the revision in table 3. However, we do not agree to include interventions into the LPA/LTA models because these models generally uses features/characteristics.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure):

Table 3 Baseline characteristics and outcomes by profiles on day 1

MCS/ECMO, n (%) 102 (12) 77 (12) 6 (5) 19 (19) 0.008

Profile 3 was more likely to use circulatory support than profile 2 (19% vs. 5%; p = 0.008).

MANUSCRIPT LOCATION: Table 3; P11 L8.

REVIEWER COMMENT: 2. I would recommend using multiple ICD-9 codes for CA rather than just one code (427.5). ICD-9-CM codes identify CA with varying accuracy and outcomes of CA vary depending on the administrative definition used. (Please refer to Vallabhajosyula et al. Mayo Clin Proc. 2020 doi: 10.1016/j.mayocp.2019.12.007).

RESPONSE: we are grateful to the reviewer for this insightful comment. We are sorry for not making the inclusion criteria clear in the original version, we searched both ICD-9 code and diagnosis including cardiac arrest, cardiopulmonary resuscitation and ventricular fibrilation. Thus, although the ICD-9 code for CPR and VF were not used, but we have actually included such patients. We added this to the revision to ensure the inlcuded patients represented cardiac arrest target population.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure): Subjects with the diagnosis of cardiopulmonary resuscitation (ICD-9 code: 9960 and 9963), cardiac arrest (ICD-9 code: 4275) and ventricular fibrillation (ICD-9 code: 4274) were screened for potential eligibility[25].

MANUSCRIPT LOCATION: P5 L15

REVIEWER COMMENT: 3. Include a section on the limitations of the study.

RESPONSE: we included a section for limitation in this round of revision.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure): Several limitations of the study must be acknowledged. First, it is well acknowledged that cardiac arrest may be followed by brain injury, systemic hypo-perfusion, and multiple organ dysfunction. However, there is no direct annotation for the reasons of CA in the database. Thus, we included coexisting diagnosis as possible reasons of the CA. Furthermore, possible reasons for CA can also be deduced by the type of ICU. For example, the possible reason of CA in CCU is most probably myocardial infarction or arrythmia, and MICU patients may suffer from multiple organ failure. Second, the study failed to find any interventions that were associated with transition patterns. Most probably, the transition pattern is an intrinsic nature of the disease, and interventions such as vasopressors and circulatory support cannot change the transition pattern. Another reason is that the interventions being explored are limited, numerous interventions are being used during post-CA care. We cannot explore all of them in one study. Third, our study showed that patients who transitioned from profile 3 to profile 1 did not demonstrate an impact on mortality compared to those who remained in profile 3. This is counterintuitive from clinical expertise. The result showed a trend that patients remained in profile 3 had 3-fold increase in mortality but the statistical significance was not reached, which could be due to the small sample size in profile 3 in the study.

MANUSCRIPT LOCATION: P19 L11

REVIEWER COMMENT: 4. If the database allows, stratifying Cardiac arrest by the etiology would enrich the paper. The clinical course, management, and outcomes of CA secondary to different etiologies (ie. MI, Sepsis, ARDS etc ) are quite distinct and targeting individual pathologies would be of benefit.

RESPONSE: we fully agree with the reviewer on this point and added these etiology into the analysis in this round of revision.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure):

Etiology, n (%) 0.008

ARF 257 (30) 175 (28) 50 (43) 32 (32)

MI 129 (15) 99 (16) 15 (13) 15 (15)

Others 293 (35) 234 (37) 30 (26) 29 (29)

Sepsis 144 (17) 109 (17) 19 (16) 16 (16)

Trauma 25 ( 3) 15 (2) 2 (2) 8 (8)

Abbreviations: ARF: acute respiratory failure; MI: myocardial infarction.

MANUSCRIPT LOCATION: Table 3

REVIEWER COMMENT: 5. In the discussion the authors mention that the transition process may reflect the treatment strategies used. Would it be possible to assess the different treatment strategies used in patients who transitioned from profile 2 and profile 3 to profile 1 compared to those who remained in their respective profiles?

RESPONSE: we are greateful to the reviewer for this valuable comments. In this revision, we performed more analysis on the differences in treatment strategy for patients with different transition pattern.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure):

Impact of therapeutic intervention on profile transition

The associations of medical interventions, such as vasoactive agents and circulatory support, with the transition pattern were explored by univariate analysis. We compared patients transitioned from profile 2 and 3 to profile 1 versus those did not transition to profile 1 (Table 5). The results showed that there was no significant difference between the two transition groups in terms of medications and mechanical circulatory support. Probably, the transition pattern is the intrinsic nature of the disease progression, there is no effective therapeutic intervention that could change the transition path.

Table 5. Comparisons between patients who transitioned from profile 2 or 3 to profile 1 versus those not transitioned to profile 1.

Variables Total (n = 216) Not transition to profile 1 (n = 51) Transition to profile 1 (n = 165) p

Age (years), Median (IQR) 66.00 (54.12, 78.10) 66.33 (55.26, 75.85) 65.44 (54.07, 78.97) 0.806

Gender, Male (%) 136 (63) 33 (65) 103 (62) 0.897

SOFA, Median (IQR) 10.00 (7.00, 12.00) 9.00 (7.00, 10.50) 10.00 (8.00, 12.00) 0.118

Dopamine use, n (%) 47 (22) 7 (14) 40 (24) 0.162

Epinephrine use, n (%) 31 (14) 7 (14) 24 (15) 1.000

Norepinephrine use, n (%) 106 (49) 21 (41) 85 (52) 0.258

Dobutamine use, n (%) 9 ( 4) 1 ( 2) 8 ( 5) 0.689

MCS/ECMO, n (%) 191 (88) 45 (88) 146 (88) 1.000

Etiology, n (%) 0.777

ARF 82 (38) 20 (39) 62 (38)

MI 30 (14) 6 (12) 24 (15)

Others 59 (27) 12 (24) 47 (28)

Sepsis 35 (16) 11 (22) 24 (15)

Trauma 10 ( 5) 2 ( 4) 8 ( 5)

Abbreviations: SOFA: sequential organ failure assessment; MCS: mechanical circulatory support; ECMO: Extracorporeal membrane oxygenation; ARF: acute respiratory failure; MI: myocardial infarction.

MANUSCRIPT LOCATION: P13 L16; Table 5.

REVIEWER COMMENT: 6. The authors discuss the impact of using the profiling of cardiac arrest patients for clinical trials. It would be informative for readers if they could discuss a proposed clinical approach / management strategy to the 3 distinct profiles encountered on day 1.

RESPONSE: We fully agree with the reviewer on this constructive suggestion. We added more analyses in this revision to explore potential beneficial effects of interventions for patients with different transition pattern, however, no intervention was found to be associted with the transition pattern. We acknowledge this limitation in the revision. Futhermore, we added more discussions on the use of different interventions on day 1.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure):

For instance, clinical trials designed to investigate agents or interventions with neurological protective property should be performed in profile 2. In a recent study, Nishikimi M and colleagues showed that the effect of mild therapeutic hypothermia was different depending on the presence or absence of hypoxic encephalopathy [30]. The effects of organ support interventions such as mechanical circulatory support (MCS) and ECMO can be investigated in profile 3 patients.

Second, the study failed to find any interventions that were associated with transition patterns. Most probably, the transition pattern is an intrinsic nature of the disease, and interventions such as vasopressors and circulatory support cannot change the transition pattern. Another reason is that the interventions being explored are limited, numerous interventions are being used during post-CA care. We cannot explore all of them in one study.

MANUSCRIPT LOCATION: P17 L24; P19 L17

Minor comments

REVIEWER COMMENT: 1. Consider discussing why the patients who transitioned from profile 3 to profile 1 did not demonstrate an impact on mortality compared to those who remained in profile 3.

RESPONSE: we added discussion on this point in the revision.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure): Third, our study showed that patients who transitioned from profile 3 to profile 1 did not demonstrate an impact on mortality compared to those who remained in profile 3, which is counterintuitive as judged by clinical expertise. The result showed a trend that patients remained in profile 3 had 3-fold increase in mortality but the statistical significance was not reached, which could be explained by the small sample size in profile 3 in the study.

MANUSCRIPT LOCATION: P19 L21

REVIEWER COMMENT: 2. Line 6 in the Introduction section tends to suggest that TTM has only shown success only in animal studies and not human studies which is not accurate as several studies demonstrated that TTM has improved survival and neurological function in patients with CA. This could be rephrased. (Please refer to the following doi:10.1161/CIR.0000000000000313; doi:10.1056/NEJMoa012689; doi:10.1056/NEJMoa003289).

RESPONSE: we rephrased this text in the revision.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure): In particular, targeted temperature management (TTM) has been shown to improve survival and neurological functions in patients with CA[9-11].

MANUSCRIPT LOCATION: P3 L8

REVIEWER COMMENT: 3. Page 18 Line 23. “In this study, we found that the profile 2 had significantly greater…” Shouldn’t it be profile 3.

RESPONSE: We are sorry for this mistake and we correct it in the revision.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure): In the study, we found that the profile 3 had significantly greater proportions of the patients on vasopressors and inotropes.

MANUSCRIPT LOCATION: P19 L2

REVIEWER COMMENT: 4. Line 9 of the discussion should be ‘transitioned to profile 1’ instead of ‘profile 3’.

RESPONSE: corrected

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure): A substantial number of patients in profile 2 (72%) and 3 (82%) on day 1 transitioned to profile 1

MANUSCRIPT LOCATION: P17 L9

REVIEWER COMMENT: 5. The last sentence of the first paragraph in the discussion section needs to be rephrased.

RESPONSE: corrected

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure): Not surprisingly, the mortality outcome was significantly better for patients transitioned to profile 1 on day 3 than those transitioned or remained in profile 2 or 3.

MANUSCRIPT LOCATION: P17 L13

Reviewer #3:

REVIEWER COMMENT: In this original manuscript entitled,” Stability of Subphenotypes of Cardiac Arrest Patients Admitted to Intensive Care Unit:

a latent transition analysis of a large critical care database”,. This is a retrospective US based critical care database study that classifies cardiac arrest into three subphenotypes using the latent transition analysis and evaluates the stability of the three subphenotypes and effects on the ICU mortality outcomes. 848 patients were included and the study demonstrates that patients who transitioned to subphenotype 3 on day 3 of hospitalization had worse survival outcomes.

RESPONSE: Thank you for the comments.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure): None

MANUSCRIPT LOCATION: None

major comments

REVIEWER COMMENT: 1. The introduction and discussion can be more focused on the implications of the stability and transition of subphenotypes

RESPONSE: We revised the introduction to meet the requirement.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure): In addition, the subphenotype transition has also been widely investigated because unraveling the transition pattern can have significant clinical and research implications[16-18]. For example, subphenotype stability over time can help to design trials and/or therapeutics. Subphenotype transition is also important to the question on whether difference in clinical presentation is dependent on the timing of measurement[16].

However, it is largely unknown whether the subphenotypes are stable or subject to transitions and how this transition can impact clinical outcomes. Other studies show that subphenotype transition can have significant clinical implications [15,16]. Thus, the current study aimed to characterize the latent transition pattern of CA patients by using latent transition analysis (LTA).

MANUSCRIPT LOCATION: P3 L17; P3 L25

REVIEWER COMMENT: 2. This study is similar to your previous study entitled ' Subphenotypes of Cardiac Arrest Patients Admitted to Intensive Care Unit: a latent profile analysis of a large critical care database. would recommend you mention the previous study and highlight the findings of the new study.

RESPONSE: we cited our previous work in the revision and added some sentences on how can the current study add new.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure): Our previous work has identified subphenotypes of CA using cross-sectional data on the first day of ICU entry [14]. However, it is largely unknown whether the subphenotypes are stable or subject to transitions and how this transition can impact clinical outcomes. Other studies show that subphenotype transition can have significant clinical implications [15,16]. Thus, the current study aimed to characterize the latent transition pattern of CA patients by using latent transition analysis (LTA). The differences in the mortality outcome for patients with different transition paths were also explored.

MANUSCRIPT LOCATION: P3 L24

Attachment

Submitted filename: rebuttal letter.docx

Decision Letter 1

Saraschandra Vallabhajosyula

15 Apr 2021

PONE-D-20-40279R1

Latent transition analysis of cardiac arrest patients treated in the intensive care unit

PLOS ONE

Dear Dr. Zhang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 30 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Saraschandra Vallabhajosyula, MD MSc

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: (No Response)

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: This paper titled “Latent transition analysis of cardiac arrest patients treated in the intensive care unit” focuses on sub-phenotypes of cardiac arrest patients on day 1 and day 3 of admission and the transition between the identified groups. The paper is scientifically sound and well written. I appreciate the efforts the authors made to address all the concerns raised by the reviewers. I would like to mention a few minor comments I have

1. The manuscript would benefit from copyediting.

2. Although the overlap with your prior manuscript has been addressed, attempts to minimize this further would be appreciated.

3. Rephrase Page 19 line 19, 20 and page 14 line 5 – The fact that there was no difference in the medications between the patients that transitioned vs those that did not transition could reflect an intrinsic nature of the disease and lack of identifiable interventions that were associated with transition. However, concluding that the interventions cannot change transition might not be appropriate as patients requiring vasopressors/ inotrope/ TTM/ circulatory support and not receiving it will surely lead to deleterious effects.

Reviewer #3: I had the opportunity to re-review the manuscript entitled " Latent transition analysis of cardiac arrest patients treated in the intensive care unit".

1.Most of the revisions that have been suggested by me and the other reviewer's and editor has been incorporated in the manuscript.

2. The manuscript has been revised to not mirror it's previous study verbatim entitled ' Subphenotypes of Cardiac Arrest Patients Admitted to Intensive Care Unit: a latent profile analysis of a large critical care database'.

3. The sub-phenotypes of CA indicate a continuum of the disease process of CA and post cardiac arrest syndrome, the manuscript is not clearly demonstrating the clinical implications (not the further research implications) of the sub-phenotypes. The future research implication of the transition of the sub-phenotypes have been discussed in detail in this revision of the manuscript. Furthermore, There is a statement that is contradicting the conclusions and the clinical implications aspect of the discussion. The authors themselves state that ' Probably, the transition pattern is the intrinsic nature of the disease progression, there is no effective therapeutic intervention that could change the transition path' . but further go on to discuss the possible interventions that could be carried out at different sub-phenotype profile. This statement has to be modified or addressed in the discussion as it is contradicting the study aim.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: Yes: Dhiran Verghese

Reviewer #3: Yes: Aditi Shankar

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 May 27;16(5):e0252318. doi: 10.1371/journal.pone.0252318.r004

Author response to Decision Letter 1


30 Apr 2021

To Dr. Saraschandra Vallabhajosyula

Academic Editor

PLOS ONE

Dear Dr. Vallabhajosyula

We thank you and reviewers for the generous comments on the manuscript and have revised the manuscript to address these concerns. Here we enclose our point-by-point responses to the comments raised by the reviewers and editors. We hope our responses and revisions made to the manuscript can address these concerns. We are looking forward to your positive response.

Yours sincerely,

Zhongheng Zhang, MD

Department of Emergency Medicine,

Sir Run Run Shaw Hospital,

Zhejiang University School of Medicine,

Hangzhou,

310016,

China.

Email: zh_zhang1984@zju.edu.cn

Reviewer #2: This paper titled “Latent transition analysis of cardiac arrest patients treated in the intensive care unit” focuses on sub-phenotypes of cardiac arrest patients on day 1 and day 3 of admission and the transition between the identified groups. The paper is scientifically sound and well written. I appreciate the efforts the authors made to address all the concerns raised by the reviewers. I would like to mention a few minor comments I have

REVIEWER COMMENT: 1. The manuscript would benefit from copyediting.

RESPONSE: the tables in the main text were edited and some other places were also editted for clarity and typos.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure): multiple places

MANUSCRIPT LOCATION: multiple places.

REVIEWER COMMENT: 2. Although the overlap with your prior manuscript has been addressed, attempts to minimize this further would be appreciated.

RESPONSE: the manuscript was revised futher to reduce overlap.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure): multiple places

MANUSCRIPT LOCATION: multiple places.

REVIEWER COMMENT: 3. Rephrase Page 19 line 19, 20 and page 14 line 5 – The fact that there was no difference in the medications between the patients that transitioned vs those that did not transition could reflect an intrinsic nature of the disease and lack of identifiable interventions that were associated with transition. However, concluding that the interventions cannot change transition might not be appropriate as patients requiring vasopressors/ inotrope/ TTM/ circulatory support and not receiving it will surely lead to deleterious effects.

RESPONSE: we fully agree with the reviewer on this point and revised the texts.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure): Second, the study failed to find any interventions that were associated with transition patterns. Most probably, the fact that there was no difference in the medications between the patients that transitioned versus those that did not transition could reflect an intrinsic nature of the disease and lack of identifiable interventions that were associated with transitions. Other reasons are that the number of interventions being explored is limited and the study may not have enough power to detect some small effect sizes.

MANUSCRIPT LOCATION: P19 L15

Reviewer #3: I had the opportunity to re-review the manuscript entitled " Latent transition analysis of cardiac arrest patients treated in the intensive care unit".

REVIEWER COMMENT: 1.Most of the revisions that have been suggested by me and the other reviewer's and editor has been incorporated in the manuscript.

RESPONSE: Thank you for the comments.

REVIEWER COMMENT: 2. The manuscript has been revised to not mirror it's previous study verbatim entitled ' Subphenotypes of Cardiac Arrest Patients Admitted to Intensive Care Unit: a latent profile analysis of a large critical care database'.

RESPONSE: Thank you for the comments.

REVIEWER COMMENT: 3. The sub-phenotypes of CA indicate a continuum of the disease process of CA and post cardiac arrest syndrome, the manuscript is not clearly demonstrating the clinical implications (not the further research implications) of the sub-phenotypes. The future research implication of the transition of the sub-phenotypes have been discussed in detail in this revision of the manuscript.

RESPONSE: we add some lines to discuss the clinical implications of the sub-phenotypes.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure):

The transition pattern of post-cardiac arrest syndrome is helpful for risk stratification, which is important for medical resource allocation and decision making. Furthermore, transition pattern might be indicative of medical interventions that can help to direct treatment, although current study failed to identify any difference in interventions across different transition patterns.

MANUSCRIPT LOCATION: P17 L20

REVIEWER COMMENT: Furthermore, There is a statement that is contradicting the conclusions and the clinical implications aspect of the discussion. The authors themselves state that ' Probably, the transition pattern is the intrinsic nature of the disease progression, there is no effective therapeutic intervention that could change the transition path' . but further go on to discuss the possible interventions that could be carried out at different sub-phenotype profile. This statement has to be modified or addressed in the discussion as it is contradicting the study aim.

RESPONSE: The statement has been modified in the revision.

RELATED REVISED MANUSCRIPT TEXT (or Table/Figure):

Second, the study failed to find any interventions that were associated with transition patterns. Most probably, the fact that there was no difference in the medications between the patients that transitioned versus those that did not transition could reflect an intrinsic nature of the disease and lack of identifiable interventions that were associated with transitions. Other reasons are that the number of interventions being explored is limited and the study may not have enough power to detect some small effect sizes.

MANUSCRIPT LOCATION: P19 L15

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 2

Saraschandra Vallabhajosyula

14 May 2021

Latent transition analysis of cardiac arrest patients treated in the intensive care unit

PONE-D-20-40279R2

Dear Dr. Zhang,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Saraschandra Vallabhajosyula, MD MSc

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Saraschandra Vallabhajosyula

18 May 2021

PONE-D-20-40279R2

 Latent transition analysis of cardiac arrest patients treated in the intensive care unit

Dear Dr. Zhang:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Saraschandra Vallabhajosyula

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: rebuttal letter.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    Data cannot be shared publicly because the data are owned by a third party and authors do not have permission to share the data. Data are available from the Beth Israel Deaconess Medical Center Institutional Data Access (via https://physionet.org/content/mimiciii/1.4/) for researchers who meet the criteria for access to confidential data.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES